A Phase 1/2 interventional study of Pralatrexate Injection and Gemcitabine Hydrochloride in Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma and Peripheral T-cell Lymphoma, sponsored by Acrotech Biopharma Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-07.
Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing gemcitabine in Hodgkin Disease — 3 open to participants now, 3 under way, none of them phase 3. Gemcitabine · Hodgkin Disease.
Among the 34 studies testing gemcitabine in Hodgkin Disease, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2007, is one of 7 in phase 1/2, and was the 18th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →3 of the 34 studies testing gemcitabine in Hodgkin Disease are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Michael Spinner, MD · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 26 · Phase 3 1
First in 1998; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 46 across the 33 interventional studies. Of the 27 that completed or were terminated, 11 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acrotech Biopharma Inc., one of the names counted as Aurobindo Pharma. Under that name alone:
Acrotech Biopharma Inc. is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Aurobindo Pharma has 1 study filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing gemcitabine in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing gemcitabine in Hodgkin Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia.
This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
This study's enrollment of 119 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Acrotech Biopharma Inc. is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Phase 1
Phase 2a
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pralatrexate Injection · Drug: Gemcitabine Hydrochloride · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid
Drug: Pralatrexate Injection · Drug: Gemcitabine Hydrochloride · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid
Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Also known as: FOLOTYN, PDX, Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin
Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions. Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Also known as: Gemcitabine, Gemzar®, Eli Lilly and Company, Gemcitabine Hydrochloride (HCl) for Injection
1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
Also known as: Cyanocobalamin
1 mg orally Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
Also known as: Vitamin B9, Folate, Folacin
Objective Responses Assessed by International Workshop Criteria (IWC)
Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done.
Time frame: Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I
Duration of Response
Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)
Time frame: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
Progression-free Survival (PFS) Time
PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).
Time frame: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
Patients were enrolled between May 2007 and July 2010 across 16 study sites, all in the United States.
| Milestone | Phase 1 Group A - Dose Finding | Phase 1 Group B - Dose Finding | Phase 1 Group C - Dose Finding | Phase 2 Group B | Phase 2 Group C |
|---|---|---|---|---|---|
| Started | 7 | 10 | 18 | 38 | 34 |
| Completed | 7 | 10 | 17 | 38 | 34 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease - pt withdrew | 0 | 0 | 1 | 0 | 0 |
Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done.
| participants | Phase 1 | Phase 2 - Group B | Phase 2 - Group C |
|---|---|---|---|
| Objective Responses Assessed by International Workshop Criteria (IWC) | 8 | 5 | 7 |
Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)
| days | Phase 1 | Phase 2 - Group B | Phase 2 - Group C |
|---|---|---|---|
| Duration of Response | 174 (35 to 288) | 210 (57 to 210) | 170 (59 to 178) |
PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).
| days | Phase 1 | Phase 2 - Group B | Phase 2 - Group C |
|---|---|---|---|
| Progression-free Survival (PFS) Time | 53.0 (49.0 to 106.0) | 59.0 (52.0 to 99.0) | 54.0 (45.0 to 89.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 | — | 18/35 (51.4%) | 35/35 (100%) |
| Phase 2 - Group B | — | 13/38 (34.2%) | 38/38 (100%) |
| Phase 2 - Group C | — | 16/34 (47.1%) | 34/34 (100%) |
| Event | Phase 1 | Phase 2 - Group B | Phase 2 - Group C |
|---|---|---|---|
| pyrexiaGeneral disorders | 2/35 | 4/38 | 7/34 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 0/35 | 0/38 | 4/34 |
| cellulitisInfections and infestations | 3/35 | 1/38 | 1/34 |
| pneumoniaInfections and infestations | 3/35 | 1/38 | 2/34 |
| renal failure acuteRenal and urinary disorders | 0/35 | 2/38 | 2/34 |
| hypoxiaRespiratory, thoracic and mediastinal disorders | 0/35 | 0/38 | 2/34 |
| neutropeniaBlood and lymphatic system disorders | 0/35 | 0/38 | 2/34 |
| stomatitisGastrointestinal disorders | 0/35 | 0/38 | 2/34 |
| hydronephrosisRenal and urinary disorders | 0/35 | 0/38 | 2/34 |
| dehydrationMetabolism and nutrition disorders | 0/35 | 0/38 | 2/34 |
| Event | Phase 1 | Phase 2 - Group B | Phase 2 - Group C |
|---|---|---|---|
| fatigueGeneral disorders | 25/35 | 18/38 | 15/34 |
| pyrexiaGeneral disorders | 23/35 | 18/38 | 15/34 |
| nauseaGastrointestinal disorders | 15/35 | 24/38 | 21/34 |
| anaemiaBlood and lymphatic system disorders | 19/35 | 14/38 | 9/34 |
| stomatitisGastrointestinal disorders | 16/35 | 9/38 | 12/34 |
| neutropeniaBlood and lymphatic system disorders | 16/35 | 14/38 | 8/34 |
| thrombocytopeniaBlood and lymphatic system disorders | 14/35 | 16/38 | 8/34 |
| diarrhoeaGastrointestinal disorders | 13/35 | 11/38 | 8/34 |
| constipationGastrointestinal disorders | 10/35 | 10/38 | 12/34 |
| vomitingGastrointestinal disorders | 12/35 | 10/38 | 9/34 |
| Age, Categorical(Participants) | Phase 1 - Group A | Phase 1 - Group B | Phase 1 - Group C | Phase 2 - Group B | Phase 2 - Group C | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 7 | 10 | 24 | 28 | 71 |
| >=65 years | 5 | 3 | 8 | 14 | 6 | 36 |
| Age, Continuous(years) | Phase 1 - Group A | Phase 1 - Group B | Phase 1 - Group C | Phase 2 - Group B | Phase 2 - Group C | Total |
|---|---|---|---|---|---|---|
| Mean | 67.6 ± 15 | 52.4 ± 18 | 57.4 ± 17 | 57.9 ± 16 | 53.2 ± 15 | 56.4 ± 16.1 |
| Sex: Female, Male(Participants) | Phase 1 - Group A | Phase 1 - Group B | Phase 1 - Group C | Phase 2 - Group B | Phase 2 - Group C | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 17 | 14 | 42 |
| Male | 3 | 7 | 14 | 21 | 20 | 65 |
| Region of Enrollment(participants) | Phase 1 - Group A | Phase 1 - Group B | Phase 1 - Group C | Phase 2 - Group B | Phase 2 - Group C | Total |
|---|---|---|---|---|---|---|
| United States | 7 | 10 | 18 | 38 | 34 | 107 |
The record gives a start of May 2007, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pralatrexate · Gemcitabine · Vitamin B 12 · Folic Acid